Background And Objectives: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening drug reactions considered to be part of a single spectrum disease.
Aim: The aim of this work is to describe the clinical and epidemiological characteristics of the complex SJS/TEN in a reference University Hospital.
Patients And Methods: Retrospective study of patients diagnosed with SJS/TEN in a Hospital provided with a reference burn unit (1989-2008).
Results: We included 71 patients, 34 SJS and 32 TEN. They presented an average of 62.5% of the body surface area affected and 25.9% of epidermal sloughing. Mucosal involvement was present in all of them. The average of suspected drugs were 2.3 per patient, being painkillers, NSAID and antiepileptic drugs the most frequent. Silver sulfadiazine was the topical treatment most frequently used and 90% received systemic steroids. A fatal outcome was present in 20% of the patients.
Conclusions: The epidemiological and clinical data were consistent with those of other series. Discontinuation of the offending drug, as well as the early admission to a burn unit are the clues for the management of SJS/TEN. Topical treatment with silver sulfadiazine has shown to be useful and safe.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.medcli.2010.12.007 | DOI Listing |
J Hazard Mater
December 2024
College of Life Science, Henan Normal University, Xinxiang 453007, China. Electronic address:
The widespread application of quantum dots (QDs) in recent years has raised concerns about potential environmental and human health risks. Although the toxicity of cadmium telluride quantum dots (CdTe QDs) has been partially studied, their effects on stem cells, tissue regeneration, neurodevelopment, and neurobehavioral toxicity remain unclear. This study aimed to investigate the combined toxic effects and mechanisms of CdTe QDs on planarians at the individual, tissue, cellular, and molecular levels.
View Article and Find Full Text PDFInvest New Drugs
January 2025
College of Pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
The understanding of pembrolizumab-induced Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN) primarily derives from case reports, leaving specific clinical features largely unknown. This study aims to investigate the clinical characteristics associated with pembrolizumab-induced SJS/TEN and to encourage the judicious use of pembrolizumab. Retrieve reports on pembrolizumab induced SJS/TEN before September 30, 2024 for retrospective analysis.
View Article and Find Full Text PDFJ Dermatol
January 2025
Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Dermatol Reports
November 2024
Pathology Department, Taibah University, Saudi Arabia.
Toxic epidermal necrolysis (TEN) is a life-threatening acute mucocutaneous syndrome. It is characterized by keratinocyte necrosis and apoptosis, which affect more than 30% of the body's surface. TEN is most commonly due to an altered immunological response to specific drugs, infections, and malignancies, or it can be idiopathic.
View Article and Find Full Text PDFFront Oncol
December 2024
Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.
The most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 inhibitor (abemaciclib, ribociclib, or palbociclib) combined with endocrine therapy. Despite CDK4/6 inhibitors being part of routine care in the last few years, new adverse events continue to be reported. Here, we report two cases of palinopsia, a rare neurological visual disturbance that refers to the persistence or recurrence of a visual image after the removal of visual stimuli in patients treated with ribociclib and letrozole.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!